Information Provided By:
Fly News Breaks for October 14, 2015
MDXG
Oct 14, 2015 | 08:09 EDT
Brean Capital noted MiMedx hosted an upbeat analyst meeting, which focused on several current and future growth opportunities. The firm sees continued growth in its core amniotic tissue platform along with margins improvement with new product technologies. Brean Capital reiterated its Buy rating and $16 price target on MiMedx shares.